TGF- treatment was found to enhance GalNAc-T enzyme activity for the synthetic peptide substrate derived from the IIICS domain defining the FDC6 epitope

TGF- treatment was found to enhance GalNAc-T enzyme activity for the synthetic peptide substrate derived from the IIICS domain defining the FDC6 epitope. 1 M EtDO-P4, the specific inhibitor of GlcCer synthase (32), did not cause a significant switch in cell morphology, manifestation of EMT marker molecules, or cell motility (Fig. 1 and Fig. S2),… Continue reading TGF- treatment was found to enhance GalNAc-T enzyme activity for the synthetic peptide substrate derived from the IIICS domain defining the FDC6 epitope